Company: INTS
Filing Date: 2025-03-28
Form Type: DRS
Source: 0001628279-25-000170
Chunk: 29

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-28
Form: DRS
Chunk 29
---
 the assumed public offering price per share paid by investors participating in this offering. The information above is illustrative only and will change based on actual pricing and other terms of this offering determined at pricing. The final public offering price will be determined through negotiation between us and the Placement Agents in the offering and may be at a discount to the current market price. Therefore, the assumed offering price used throughout this prospectus may not be indicative of the final public offering price.

The following table illustrates this dilution on a per share basis:

| Assumed public offering price per share                                                      |     |   |      |     | $ |
| Net tangible book value per share as of December 31, 2024                                    |     | $ | 0.18 |     |   |
| Increase in net tangible book value per share attributable to new investors in this offering |     | $ |      |     |   |
| As adjusted net tangible book value per share after this offering                            |     |   |      |     | $ |
| Dilution in net tangible book value per share to new investors in this offering              |     |   |      |     | $ |

Each $1.00 increase or decrease in the assumed public offering price of $ per share, the last reported sale price of our Common Stock on the Nasdaq Capital Market on , 2025, would increase or decrease our pro forma as-adjusted net tangible book value per share after this offering by $ per share. Each $1.00 increase or decrease in the assumed public offering price would decrease or increase the accretion per share to new investors by $ , assuming that the number of shares of Common Stock offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase of 100,000 shares of Common Stock offered by us would decrease the pro forma as adjusted net tangible book value after this offering by $ per share and decrease the accretion per share to new investors by $ , and a decrease of 100,000 shares of Common Stock offered by us would increase the pro forma as adjusted net tangible book value by $ per share and increase the accretion per share to new investors by $ , assuming that the assumed public offering price remains the same, and after deducting estimated Placement Agents’ fees and estimated offering expenses payable by us.

The table and discussion above are based on 15,122,873 shares of Common Stock